中文摘要：

干扰素诱导蛋白-10（IP-10）属于ELR—CXC类趋化因子，是目前研究较多的一个分子，其唯一的受体是CXCR3。IP-10与其受体特异性结合后，可以发挥抑制新生血管的形成及抗纤维化的作用，该生物学功能也参与新生血管性眼病的发病进程。研究证实，IP-10与亚临床慢性炎症紧密相关，参与年龄相关性黄斑变性（AMD）的发病过程，可能成为一项AMD发病的临床检测指标；表达于脉络膜新生血管内皮细胞上的IP-10／CXCR3信号通路有抑制脉络膜新生血管的作用；此外，IP-10在AMD患眼病灶内的高表达可能与血管内皮生长因子表达升高，反馈性诱导负性调控因子（IP-10等）生成相关。IP-10参与糖尿病视网膜病变（DR）的发病过程中，可用于临床检测DR病情的严重程度及预后评估的新指标，以及可能具有使增生性DR（PDR）患者活动期新生血管生成中止、促进新生血管纤维化的作用，从而抑制PDR的发展。IP-10可通过下调炎症细胞促血管生成因子表达的间接作用以及通过抑制血管内皮细胞迁移和管腔形成的作用直接减少角膜新生血管的生成。IP-10可能参与早产儿视网膜病变和脉络膜息肉样病变的发病过程。鉴于其独特的生物学功能，有望运用IP-10作为靶点进行临床靶向治疗达到抑制新生血管性眼病的目的。本文就近年来IP-10与几种常见新生血管性眼病关系的研究进展进行综述。

英文摘要：

Interferon-inducible protein-10 （IP-10） is a member of the ELR-CXC-chemokine family, a molecule which is paid close attention to current studies. IP-10 can inhibit neovaseularization and exert its function on anti-fibrosis as it binds with CXCR3 ,the only specific receptor to IP-10. Accumulating evidences revealed that IP-10 also involved in the pathologic process of ocular neovascular diseases. It shows that IP-10 was closely associated with subclinical chronic inflammation and involved in the development of age-related macular degeneration （AMD） ,which would be used as a clinical biomaker to make a definite diagnosis of AMD. The IP-10/CXCR3 signal,expressed on the choroidal endothelial cells, had the ability of suppressing ehoroidal neovaseularization. Moreover, the over expression of IP-10 in the lesions of AMD may be attributed to the induction efficacy of promoting anti-angiogenie factor expression, such as IP-10 by vascular endothelial growth factor. IP-10 had an important role in the pathogenic process of diabetic retinopathy （DR） and might be used as a new indicator to evaluate the severity and prognosis of DR. And IP-10 may have the ability to suppress proliferative DR by interrupting formation of new vessels and promoting fibrosis of new vessels. Experimental study showed that IP-10 can reduce corneal neovaseularization by down-regulating the expression of proangiogenic cytokines indirectly and suppressing the migration of vascular endothelial cells and tubegenesis directly. IP-IO is involved in the development of retinopathy of prematurity and polypoidal choroidal vaseulopathy. Given its unique biological characteristics,IP-10 is expected to be a molecular target to inhibit neovaseularization in treatment for ocular neovascular diseases. This article reviews the recent progress in the studies on relationship between IP-10 and several common neovascular eve diseases.